Guidelines for the use of platelet transfusions

These guidelines are based on many years experience in the use of platelet transfusions by the authors, on searching the literature in MedLine and other databases using appropriate keywords, and a review of the existing guidelines published by expert groups [British Committee for Standards in Haematology (BCSH), 1992; Schiffer et al, 2001], including a previous guideline on platelet transfusions (BCSH, 1992) and the recommendations of Consensus Conferences (National Institutes of Health Consensus Conference, 1987; Consensus Conference on Platelet Transfusion, 1998). The section on indications for platelet transfusions was drafted in collaboration with the Haemato-Oncology Task Force of the BCSH. The authors were selected to encompass a wide range of interests in platelet transfusion therapy, including clinical and laboratory haematology, paediatrics, surgery, anaesthetics and critical care, and nursing.

[1]  C. Hillyer,et al.  Methods for the reduction of transfusion‐transmitted cytomegalovirus infection: filtration versus the use of seronegative donor units , 1994, Transfusion.

[2]  J. George,et al.  The clinical importance of acquired abnormalities of platelet function. , 1991, The New England journal of medicine.

[3]  V. Novotny.  Prevention and Management of Platelet Transfusion Refractoriness , 1999, Vox Sanguinis.

[4]  N. Modi,et al.  Guidelines for the administration of blood products. , 1995, Archives of disease in childhood.

[5]  D Stainsby,et al.  Management of massive blood loss: a template guideline. , 2000, British journal of anaesthesia.

[6]  J. Holland,et al.  The Prophylactic Treatment of Thrombocytopenic Leukemic Patients with Platelets: a Double Blind Study , 1974, Transfusion.

[7]  F. Cotter,et al.  British Journal of Haematology , 1955 .

[8]  W. Ouwehand,et al.  Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy , 2003, British journal of haematology.

[9]  Richard J. Jones,et al.  Acute bleeding after bone marrow transplantation (BMT)- incidence and effect on survival. A quantitative analysis in 1,402 patients. , 1998, Blood.

[10]  A. Brand.  Alloimmune platelet refractoriness:incidence declines, unsolved problems persist , 2001, Transfusion.

[11]  P. Terasaki,et al.  Suppression of transfusion-related alloimmunization in intensively treated cancer patients. , 1981, Blood.

[12]  L. Gordon,et al.  Deleterious effects of platelet transfusions and recovery thrombocytosis in patients with thrombotic microangiopathy. , 1987, Seminars in hematology.

[13]  G. Schoch,et al.  A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. , 1995, Blood.

[14]  N. Goulden,et al.  The impact of transfusion of leucodepleted platelet concentrates on cytomegalovirus disease after allogeneic stem cell transplantation , 2002, British journal of haematology.

[15]  A. E. Horvath,et al.  Practice parameter for the use of fresh-frozen plasma, cryoprecipitate, and platelets. Fresh-Frozen Plasma, Cryoprecipitate, and Platelets Administration Practice Guidelines Development Task Force of the College of American Pathologists. , 1994, JAMA.

[16]  Knowles,et al.  The administration of blood and blood components and the management of transfused patients , 1999, Transfusion medicine.

[17]  M. Greaves,et al.  Guidelines on the investigation and management of thrombocytopenia in pregnancy and neonatal alloimmune thrombocytopenia , 1997, British journal of obstetrics and gynaecology.

[18]  J. George,et al.  Glanzmann's thrombasthenia: the spectrum of clinical disease. , 1990, Blood.

[19]  S. Lewis.  British Committee for Standards in Haematology , 1969 .

[20]  Edward J. Lee,et al.  The value of 10‐minute posttransfusion platelet counts , 1988, Transfusion.

[21]  M. Goldman.  Safety and cost effectiveness of a 10×109/L trigger for prophylactic platelet transfusions compared with the traditional 20×109/L trigger: A prospective comparative trial in 105 patients with acute myeloid leukemia , 1999 .

[22]  C. Manno,et al.  Does red‐cell T activation matter? , 2001, British journal of haematology.

[23]  H. Lamberson,et al.  Prevention of transfusion‐transmitted cytomegalovirus infection , 1992, Transfusion.

[24]  Knowles,et al.  Guidelines on the clinical use of leucocyte‐depleted blood components , 1998, Transfusion medicine.

[25]  J. Menitove.  Immunoprophylaxis for D- patients receiving platelet transfusions from D+ [correction of D-] donors? , 2002, Transfusion.

[26]  J. Fehr,et al.  Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia , 1991, The Lancet.

[27]  B. Hunt,et al.  Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias , 2003, British journal of haematology.

[28]  R. Strauss,et al.  Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  B. Squires.  Reducing risk. , 1992, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[30]  T. Lister,et al.  Relative Importance of Immune and Non‐Immune Causes of Platelet Refractoriness , 1994, Vox sanguinis.

[31]  Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. , 1997, The New England journal of medicine.

[32]  J. Vose,et al.  A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation. , 1998, Blood.

[33]  J M Rainey,et al.  Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J P AuBuchon,et al.  Platelet transfusion therapy. , 1996, Clinics in laboratory medicine.

[35]  P. Rebulla,et al.  A comparative analysis of different methods for routine blood component preparation. , 1997, Transfusion medicine reviews.

[36]  E. Ambinder,et al.  In Vitro and in Vivo Comparison of Single‐Donor Platelets and Multiple‐Donor Pooled Platelets Transfusions in Leukemic Patients , 1978, Transfusion.

[37]  B. Hunt,et al.  Indications for therapeutic platelet transfusions. , 1998, Blood reviews.

[38]  E. Freireich.  Supportive care for patients with blood disorders. , 2000, British journal of haematology.

[39]  J. Wood,et al.  Guidelines for transfusion for massive blood loss , 1988 .

[40]  J. Biebuyck,et al.  BRITISH JOURNAL OF ANAESTHESIA , 2005 .

[41]  J. Moake,et al.  Heparin‐induced thrombocytopenia: Association with a platelet aggregating factor and arterial thromboses , 1979, American journal of hematology.

[42]  T. Barbui,et al.  The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. , 1997, The New England journal of medicine.

[43]  S. Slichter.  Controversies in platelet transfusion therapy. , 1980, Annual review of medicine.

[44]  J. Menitove.  Immunoprophylaxis for D− patients receiving platelet transfusions from D−donors? , 2002 .

[45]  C. Martínez,et al.  Clinical results of a stringent policy on prophylactic platelet transfusion: non-randomized comparative analysis in 190 bone marrow transplant patients from a single institution. , 1996, Bone marrow transplantation.

[46]  S. Hiippala.  Replacement of Massive Blood Loss , 1998, Vox sanguinis.

[47]  J. Byrnes,et al.  Hazard of platelet transfusion in thrombotic thrombocytopenic purpura. , 1981, JAMA.

[48]  C. Mueller-Eckhardt,et al.  High-dose IgG treatment for neonatal alloimmune thrombocytopenia , 1989, Blut.

[49]  A. Reiner,et al.  RBC T activation and hemolysis: implications for pediatric transfusion management , 2000, Transfusion.

[50]  B. Chong,et al.  Heparin-induced Thrombocytopenia: Towards Consensus , 1998, Thrombosis and Haemostasis.

[51]  K. Yuen,et al.  Clinical factors influencing the efficacy of pooled platelet transfusions. , 1988, Blood.

[52]  G. Delage,et al.  The role of leukodepletion in the control of transfusion-transmitted disease. , 1995, Transfusion medicine reviews.

[53]  P. Dendy,et al.  Guidelines on gamma irradiation of blood components for the prevention of transfusion‐associated graft‐versus‐host disease , 1996, Transfusion medicine.

[54]  N. Grunnet,et al.  High-Dose Intravenous Immunoglobulin for Post-Transfusion Purpura , 2009 .

[55]  H. Greinix,et al.  Platelet‐reactive HLA antibodies associated with low posttransfusion platelet increments:a comparison between the monoclonal antibody‐specific immobilization of platelet antigens assay and the lymphocytotoxicity test , 2001, Transfusion.

[56]  A. Laupacis,et al.  Prevention of posttransfusion CMV in the era of universal WBC reduction: a consensus statement , 2001, Transfusion.

[57]  T. Simon,et al.  Controlled trial of routine administration of platelet concentrates in cardiopulmonary bypass surgery. , 1984, The Annals of thoracic surgery.

[58]  A. Chetrit,et al.  A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. , 1995, Leukemia & lymphoma.

[59]  P J Horsey,et al.  Multiple trauma and massive transfusion , 1997, Anaesthesia.

[60]  W. Ouwehand,et al.  Provision of platelets for severe neonatal alloimmune thrombocytopenia. , 1997, British journal of haematology.

[61]  N. Luban,et al.  T activation , 2001, British journal of haematology.